Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 242 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Water-Electrolyte Imbalances Clear all
Terminated Phase 4 Interventional Results available

Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On

NCT03597035
View directory record Official record
Conditions
Type2 Diabetes, Hyperkalemia
Interventions
Spironolactone
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
45 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Oct 21, 2026, 5:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients

NCT00415584
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Hypercalcemia
Interventions
Cinacalcet HCl
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

NCT00478192
View directory record Official record
Conditions
Hyponatremia
Interventions
Conivaptan, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
21
States / cities
Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 21, 2026, 5:32 PM EDT
Completed No phase listed Observational

Evaluation of One-day Polyethylene Glycol Powder Solution for Colonoscopy in Children

NCT01626040
View directory record Official record
Conditions
Water-Electrolyte Imbalance
Interventions
polyethylene glycol powder
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 18 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 21, 2026, 5:32 PM EDT
Not listed Phase 1 Interventional

Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial)

NCT04727840
View directory record Official record
Conditions
Chronic Kidney Diseases, Hyperkalemia
Interventions
Sodium Zirconium Cyclosilicate Oral Product
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 21, 2026, 5:32 PM EDT
Withdrawn Phase 4 Interventional

The Effects of Alendronate After Cure of Primary Hyperparathyroidism

NCT00359385
View directory record Official record
Conditions
Hyperparathyroidism
Interventions
Alendronate 70mg weekly
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

NCT00264914
View directory record Official record
Conditions
Inappropriate ADH Syndrome, Hyponatremia
Interventions
SR121463B
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 4 Interventional Results available

Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®

NCT00668200
View directory record Official record
Conditions
Paget's Disease of the Bone, Hypocalcemia
Interventions
Reclast (ZOL446, zoledronic acid), Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • Tucson, Arizona • Gainesville, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 21, 2026, 5:32 PM EDT
Terminated Phase 2 Interventional

A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia

NCT03018067
View directory record Official record
Conditions
Hyperkalemia
Interventions
RDX227675, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function

NCT00887627
View directory record Official record
Conditions
Kidney Diseases, Hyponatremia
Interventions
conivaptan hydrochloride
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of AMP Human Sodium Bicarbonate Lotion on Hydration

NCT04598386
View directory record Official record
Conditions
Fluid Retention, Fluid Loss, Sodium Retention, Cognitive Change, Heat Exposure, Hyperhydration, Electrolyte and Fluid Balance Conditions
Interventions
PR Lotion - AMP Human Performance, Placebo Lotion
Other
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 21, 2026, 5:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Using Hydration Monitor to Detect Changes in the Hydration Status Athletes

NCT02206581
View directory record Official record
Conditions
Dehydration
Interventions
Hydration Monitor
Device
Lead sponsor
Artann Laboratories
Industry
Eligibility
18 Years to 25 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boone, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 21, 2026, 5:32 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Dietary Sodium, Oxidative Stress, and Pulsatile Hemodynamics

NCT04233957
View directory record Official record
Conditions
Sodium Excess
Interventions
High Sodium, Placebo
Dietary Supplement · Other
Lead sponsor
University of Delaware
Other
Eligibility
21 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of a Caffeinated Sports Drink on Performance

NCT06721793
View directory record Official record
Conditions
Dehydration, Dehydration Related to Exercise
Interventions
carbohydrate electrolyte drink, no-sugar electrolyte drink, Caffeinated Carbohydrate and electrolyte drink, Water (Placebo)
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 21, 2026, 5:32 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Non-Invasive Optical Spectroscopic Methods for Dehydration Identification in Marathon Trainees

NCT01981902
View directory record Official record
Conditions
Dehydration
Interventions
Non-Invasive Optical Spectroscopic
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 21, 2026, 5:32 PM EDT
Terminated Not applicable Interventional

Tolvaptan for Patients With Acute Neurological Injuries

NCT02545114
View directory record Official record
Conditions
Hyponatremia, SIADH
Interventions
Tolvaptan
Drug
Lead sponsor
Polderman, Kees, H., MD, PhD
Individual
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 21, 2026, 5:32 PM EDT
Completed No phase listed Observational

Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia

NCT04566653
View directory record Official record
Conditions
Chronic Kidney Disease + Hyperkalaemia +/- Heart Failure
Interventions
Calcium Polystyrene Sulphonate 15g/60 mL water, Lokelma® 5 g/45mL water, Lokelma® 10 g/45 mL water, Veltassa® 8,4 g/80mL water, Sodium Polystyrene Sulphonate 15g/60 mL water
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Temple Terrace, Florida • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 21, 2026, 5:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Natural History of Apparent Mineralocorticoid Excess Syndrome

NCT00474942
View directory record Official record
Conditions
Apparent Mineralocorticoid Excess Syndrome
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
2
States / cities
New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 21, 2026, 5:32 PM EDT
Not listed Phase 2Phase 3 Interventional

ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study

NCT02155803
View directory record Official record
Conditions
Sarcoidosis, Hypercalcemia Due to Sarcoidosis
Interventions
ACTHAR Gel (adrenocorticotropic hormone)
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 21, 2026, 5:32 PM EDT
Completed No phase listed Observational

Tracking Treatment Pathways in Adult Patients With Hyperkalemia.

NCT05408039
View directory record Official record
Conditions
Hyperkalemia
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Huntsville, Alabama • La Jolla, California • Rancho Cucamonga, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Boluses of Ringer's in Surgical Kids (BRiSK Study)

NCT05285371
View directory record Official record
Conditions
Dehydration in Children, Fluid Therapy
Interventions
Urinalysis (UA), Complete Metabolic Panel (CMP), Glucose Stick Test (d-Stick), Medical Chart Review
Diagnostic Test · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 21 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism

NCT01199614
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
open-label PTH(1-84)
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 3 Interventional

Cinacalcet to Treat Familial Primary Hyperparathyroidism

NCT00325104
View directory record Official record
Conditions
Hypercalcemia, Familial Primary Hyperparathyroidism
Interventions
Parathyroid hormone testing, Serum calcium testing
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Studies of Elevated Parathyroid Activity

NCT00001277
View directory record Official record
Conditions
Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm, Multiple Endocrine Neoplasia, MEN1
Interventions
68Ga-Dotatate, 18F-DOPA
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Months and older
Enrollment
1,553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 21, 2026, 5:32 PM EDT